FindTrial
Sign In

DAPT

DRUG10 trials

Sponsors

CeloNova BioSciences, Inc., Abbott Medical Devices, Assistance Publique - Hôpitaux de Paris, Duk-Woo Park, MD, Shanghai Zhongshan Hospital

Conditions

AnemiaAnticoagulationAortic Valve StenosisAtrial AppendageAtrial FibrillationBleeding DisorderCirculatory System Nutritional, Metabolic, EndocrineCoagulation Disorder

Phase 2

Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban In Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure
CompletedNCT03273322
Assistance Publique - Hôpitaux de ParisAtrial Appendage, Atrial Fibrillation, Hemorrhage
Start: 2017-09-13End: 2019-09-30Updated: 2021-12-21

Phase 4

Anticoagulant Versus Dual Antiplatelet Therapy for Preventing Leaflet Thrombosis and Cerebral Embolization After Transcatheter Aortic Valve Replacement
CompletedNCT03284827
Duk-Woo Park, MDAortic Valve Stenosis
Start: 2018-03-15End: 2021-11-05Updated: 2021-11-08
Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO
NCT04135677
Shanghai Zhongshan HospitalLeft Atrial Appendage Thrombosis, Stroke, Thrombi
Start: 2022-11-11End: 2024-10-30Target: 826Updated: 2022-11-15
Antithrombotic Therapy After Coronary Artery Bypass Grafting Combined With Coronary Endarterectomy
RecruitingNCT05782270
China National Center for Cardiovascular DiseasesAnticoagulation, Coronary Endarterectomy
Start: 2023-04-11End: 2026-05-30Target: 202Updated: 2025-11-18
Century Clot-Guided Prophylactic Rivaroxaban for Post STEMI Complicating Left Ventricular Thrombus
RecruitingNCT06013020
Zunyi Medical CollegeSTEMI - ST Elevation Myocardial Infarction
Start: 2024-04-01End: 2027-12-31Target: 374Updated: 2024-03-19
Lacunar Stroke hyperAcute Clinical Utilization of Novel Approach Regimens: Rt-PA vs. DAPT Randomised Clinical Trial
RecruitingNCT07111559
Nippon Medical SchoolIschemic Stroke, Lacunar Stroke, Stroke
Start: 2025-08-01End: 2029-03-31Target: 500Updated: 2026-02-03

Unknown Phase

COBRA SHIELD OCT Study
TerminatedNCT02224235
CeloNova BioSciences, Inc.Stable Angina
Start: 2014-06-30End: 2015-06-30Updated: 2020-10-06
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
CompletedNCT03218787
Abbott Medical DevicesCoronary Artery Lesions
Start: 2017-07-19End: 2020-09-04Updated: 2021-11-05
XIENCE 28 Global Study
CompletedNCT03355742
Abbott Medical DevicesAnemia, Bleeding Disorder, Coagulation Disorder +6
Start: 2018-02-09End: 2020-04-30Updated: 2021-03-04
Ticagrelor Alone After 3 Months vs 12 Months of Dual Antiplatelet Therapy in Diabetic Patients With Acute Coronary Syndrome Undergoing PCI
Active, not recruitingPACTR202511832264697
Ain Shams UniversityCirculatory System Nutritional, Metabolic, Endocrine
Start: 2022-11-01Target: 400Updated: 2026-01-27

Related Papers

Evaluation of safety and affection of variable duration of dual antiplatelet therapy using aspirin plus ticagrelor after successful percutaneous coronary intervention for diabetic patients with acute coronary syndrome
BMC Cardiovascular Disorders2026-03-27
Postoperative antithrombotic therapy after coronary artery bypass grafting combined with coronary endarterectomy (PATH-CARE): study protocol for a randomised controlled clinical trial.
2025-11-09
Effect of cerebral embolic protection device on new cerebral embolism during transcatheter aortic valve replacement: A prospective sentinel registry.
2025-08-14
Frequency, Predictors, and Clinical Impact of Valvular and Perivalvular Thrombus After Transcatheter Aortic Valve Replacement.
2023-12-0112 citations
Impact of leaflet thrombosis on valve haemodynamic status after transcatheter aortic valve replacement
Heart2023-08-166 citations
Edoxaban Versus Dual Antiplatelet Therapy for Leaflet Thrombosis and Cerebral Thromboembolism After TAVR: The ADAPT-TAVR Randomized Clinical Trial
Circulation2022-04-0486 citations
Duration of Dual Antiplatelet Therapy for Patients at High Bleeding Risk Undergoing PCI
Journal of the American College of Cardiology2021-11-0172 citations
Rationale and design of the ADAPT-TAVR trial: a randomised comparison of edoxaban and dual antiplatelet therapy for prevention of leaflet thrombosis and cerebral embolisation after transcatheter aortic valve replacement
BMJ Open2021-01-0112 citations
Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure
Circulation Cardiovascular Interventions2020-07-0171 citations